劲方医药-B(02595.HK)预计9月19日上市 引入RTW基金等多家基石

Core Viewpoint - The company, Jinfang Pharmaceutical-B, is planning a global offering of 77.6 million H-shares, with a proposed price of HKD 20.39 per share, aiming to raise approximately HKD 1.4436 billion for further development of its core products and other candidates [1][2]. Group 1: Offering Details - The company intends to offer 77.6 million H-shares, with 7.76 million shares available in Hong Kong and 69.84 million shares for international investors [1]. - The subscription period for the shares is set from September 11 to September 16, 2025, with trading expected to commence on September 19, 2025 [1]. - The company has appointed CITIC Securities as the sole sponsor for the offering [1]. Group 2: Use of Proceeds - Approximately 71% of the net proceeds from the global offering will be allocated to the further development of core products GFH925 and GFH375 [2]. - About 19% of the net proceeds will be used for the development of other candidate products, including GFH312, GFS202A, GFH276, GFS784, and other preclinical candidates [2]. - The remaining 10% of the net proceeds will be utilized for operational expenses and other general corporate purposes [2]. Group 3: Cornerstone Investment - The company has entered into cornerstone investment agreements, with investors agreeing to subscribe for shares totaling USD 100 million (approximately HKD 780 million) under certain conditions [2]. - The cornerstone investors include notable entities such as RTW Fund, TruMed, OrbiMed, UBS Asset Management (Singapore) Ltd., Vivo Fund, and others [2]. - Assuming the offering price of HKD 20.39 per share, cornerstone investors are expected to purchase a total of 38.234 million shares [2].